News Direct

Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

financewire — Tue, 06 Oct 2026 16:30:51 +0000

Pune, India, October 6th, 2026, NewsDirect

This is a paid advertisement.

Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) has entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of Thermo Fisher Scientific. The agreement covers implementation of Quantum’s Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) for multiple sclerosis (“MS”). The company said the contract is an important milestone in the clinical development of Lucid-MS. It also marks the start of formal study start-up activities.

The agreement follows the company’s receipt of FDA clearance to proceed with the planned Phase 2 trial. Under the contract, Thermo Fisher will support Quantum BioPharma in implementing the trial. This includes study start-up activities and related clinical research services. The PPD Clinical Research Business within Thermo Fisher is a global contract research organization. It has experience supporting clinical programs across therapeutic areas, including central nervous system (“CNS”) and MS studies.

The Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of MS. The randomized, double-blind, placebo-controlled study is designed to evaluate clinical and radiological endpoints relevant to disease progression and disease biology.

“We are pleased to enter into a contract with the clinical research business of Thermo Fisher as we advance the Lucid-MS program toward Phase 2,” said Zeeshan Saeed, Chief Executive Officer of Quantum BioPharma. “Following FDA clearance to proceed with the Phase 2 study, initiating study start-up activities with a leading global CRO with extensive CNS and MS experience represents an important next step.”

Andrzej Chruscinski, President, Scientific and Clinical Affairs at Quantum BioPharma, said Lucid-MS is designed around a neuroprotective approach that targets demyelination rather than solely modulating the immune system. He added that the Phase 2 study will provide an opportunity to evaluate this approach using clinical and radiological measures.

According to the company, MS affects approximately 2.8 million people worldwide, citing the Atlas of MS, Third Edition. The company also cited Grand View Research projections that the MS therapeutic market will exceed $38 billion by 2030.

Other Nasdaq-listed companies in the biotech sector include Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), Krystal Biotech, Inc. (NASDAQ: KRYS), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and BridgeBio Pharma, Inc. (NASDAQ: BBIO).

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly Celly Nutrition Corp.). Quantum retains ownership of 19.48% of Unbuzzd as of June 30, 2026. The agreement with Unbuzzd includes royalty payments of 7% of sales from unbuzzd until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For more information visit www.quantumbiopharma.com.

Disclaimer

This article is a paid advertisement. USA Stock Report, a property of Akchirpy Media LLP, has been compensated Five thousand USD by FinnCom, Inc. for ticker tagging coverage of Quantum BioPharma Ltd. (NASDAQ: QNTM) for a period of October 6th to October 8th, 2026. FinnCom, Inc. may have been compensated by Quantum BioPharma Ltd. or a third party for this coverage. USA Stock Report has not been informed of the source or amount of any such compensation. This compensation creates a conflict of interest, and readers should consider it when evaluating this content. USA Stock Report and Akchirpy Media LLP do not hold any position in the securities mentioned and will not trade them during the compensation period. We have received no compensation from Recursion Pharmaceuticals, Inc., Krystal Biotech, Inc., Vertex Pharmaceuticals Incorporated or BridgeBio Pharma, Inc. These companies are mentioned for informational purposes only.

The information in this article is based on public press releases issued by Quantum BioPharma Ltd. We have not independently verified this information. This article is not an offer to buy or sell any security. It is not investment, legal or tax advice. Investing in securities, particularly biotech and small-cap stocks, involves a high degree of risk, including the possible loss of your entire investment. Readers should conduct their own research and consult a licensed financial advisor before making any investment decision.

This article contains forward-looking statements, including statements about the planned Phase 2 trial of Lucid-MS, clinical development and market opportunity. These statements involve risks and uncertainties, and actual results may differ materially. Readers should review the company’s filings with the SEC at www.sec.gov for a full discussion of risk factors.

Source: https://finance.yahoo.com/healthcare/articles/quantum-biopharma-signs-contract-thermo-100000238.html

Contact

Editor
Ash K
UsaStockReport
[email protected]

BOXABL (NASDAQ: BXBL) Adds Former EY Audit Partner Timothy Goldsmith to Board as Audit Committee Chair

financewire — Tue, 06 Oct 2026 16:16:56 +0000

Austin, Texas, United States, October 6th, 2026, NewsDirect

PAID ADVERTISEMENT. This article is a paid advertisement for BOXABL Inc. (Nasdaq: BXBL), distributed by NetworkNewsWire (“NNW”), a division of InvestorBrandNetwork (“IBN”). IBN has been compensated for advertising and digital media services related to BOXABL Inc. Readers should review the full disclaimer at the foot of this article before making any investment decision.

BOXABL (NASDAQ: BXBL), an innovative technology company transforming the housing market with its modular building systems, has appointed former EY audit partner Timothy Goldsmith, CPA, as a director and chair of its Audit Committee, adding public-company accounting and regulatory experience as the factory-built housing company expands its financial and…

Contact

IBN
www.InvestorBrandNetwork.com
[email protected]

Greenland Mines (NASDAQ: GRML) Exercises Option to Increase AnorTech Stake to 19.9%

financewire — Tue, 06 Oct 2026 16:16:32 +0000

Austin, Texas, United States, October 6th, 2026, NewsDirect

Greenland Mines (NASDAQ: GRML) (FSE: HK6), a Greenland-focused critical-minerals development company, exercised in full its option to acquire an additional 9.9% of AnorTech, increasing its ownership to 19.9%. Greenland Mines will acquire 25,168,669 AnorTech common shares at a deemed price of C$0.30 per share for aggregate consideration of approximately US$5.3 million, or C$7.55 million, satisfied through the issuance of Greenland Mines common shares. Following completion, Greenland Mines will hold 45,127,172 AnorTech shares. The transaction remains subject to TSX Venture Exchange acceptance and customary closing conditions.

AnorTech is advancing its 100%-owned Gronne Bjerg anorthosite project near Nuuk, Greenland, along with technologies targeting smelter-grade and high-purity alumina, CO2-free cement and other industrial materials. Greenland Mines said the increased investment also provides exposure to potential lunar applications for anorthosite, which can be used as an analogue for lunar highlands geology and in lunar regolith simulants. AnorTech reports it has supplied anorthosite to space-sector researchers and has advanced research involving lunar simulants, 3D-printable construction materials and refractory concretes and cements.

To view the full press release, visit: https://nnw.fm/wIx6e

About Greenland Mines Ltd

Greenland Mines Ltd is a Nasdaq-listed resource development and mining company focused on the development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and select midstream processing opportunities, while advancing its assets and broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML

Corporate Communications

IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]

Contact

IBN
www.InvestorBrandNetwork.com
[email protected]

Silynxcom (NYSE American: SYNX) Receives Two Purchase Orders Totalling Approximately $400,000 From a Leader in Global Defense

financewire — Tue, 06 Oct 2026 16:00:59 +0000

Austin, Texas, October 6th, 2026, NewsDirect

Silynxcom recently received two purchase orders for Silynxcom’s CLARUS In-Ear Headset products totalling approximately $400,000, are from a leading global defense company.
The primary importance of the orders, designated for a European army, is that they reflect continued demand from European defense customers.
The orders show Silynxcom’s strong relationship with a leading global defense company and a growing reputation among European forces.

Silynxcom (NYSE American: SYNX), a manufacturer and developer of ruggedized tactical communication and hearing-protection devices, as well as other gear and accessories, recently announced that it received two consecutive purchase orders from a leading global defense company, totalling around $400,000 (https://ibn.fm/mfabV).

These orders were for Silynxcom’s CLARUS In-Ear Headset system family of products, and the systems are designated for a European army. The CLARUS system is a fully modular tactical communication system that offers…

Contact

IBN
www.InvestorBrandNetwork.com
[email protected]

Quantum BioPharma (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

financewire — Tue, 06 Oct 2026 16:00:28 +0000

Austin, Texas, United States, October 6th, 2026, NewsDirect

Quantum BioPharma (NASDAQ: QNTM) entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) for multiple sclerosis (“MS”). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial. Thermo Fisher will support study start-up and related clinical research services through its PPD(TM) Clinical Research Business.

Quantum BioPharma said the randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (“PAD2”), an enzyme implicated in myelin degradation.

To view the full press release, visit https://ibn.fm/CZH9U

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Corporate Communications

IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]

Contact

IBN
www.InvestorBrandNetwork.com
[email protected]

Beeline Holdings (NASDAQ: BLNE) Expects Q3 Revenue to Reach Second-Highest Level in Company History, Prepares HEI Launch

financewire — Tue, 06 Oct 2026 16:00:06 +0000

Austin, Texas, United States, October 6th, 2026, NewsDirect

Beeline Holdings (NASDAQ: BLNE) provided a preliminary update on third-quarter 2026 performance, expecting revenue to reach the second-highest quarterly level in company history and the highest since 2021, while achieving its highest margins to date. Beeline also expects its net loss to decline from Q2, adjusted EBITDA loss to improve to its lowest level in five years and its quarter-end cash position to be at least 50% higher than at the end of Q2. Management attributed the expected improvement in part to its April shift toward Non-QM lending, particularly debt-service coverage ratio (“DSCR”) and Bank Statement loans for property investors and self-employed borrowers.

Beeline also announced the pending launch of a Home Equity Investment (“HEI”) product designed to give homeowners access to home equity without traditional income documentation or required monthly payments. Structured as a loan, the HEI may carry a 10-year term or align with the remaining term of an existing mortgage, with credit scores as low as 500 potentially eligible in certain circumstances. Beeline said the product will broaden its home-finance platform and reduce its dependence on traditional mortgage cycles and interest-rate movements.

To view the full press release, visit https://ibn.fm/OVCy8

About Beeline Holdings, Inc.

Beeline Holdings, Inc. is a technology-driven mortgage and home-finance company focused on simplifying and accelerating the path to homeownership, property investment and home-equity access. Through its digital platform, Beeline offers mortgage products designed for traditional borrowers, self-employed borrowers and real estate investors and is expanding its platform into home equity investment products.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE

Corporate Communications

IBN

Austin, Texas

www.IBN.ai

512.354.7000 Office

[email protected]

Contact

IBN
www.InvestorBrandNetwork.com
[email protected]

ZenaTech Advances ZenaDrone 2000 Heavy-Lift Interceptor Toward Flight Testing for Counter-UAS and Maritime Defense

financewire — Tue, 06 Oct 2026 14:19:35 +0000

Vancouver, British Columbia, October 6th, 2026, NewsDirect

Gasoline-powered platform designed for more than four hours of hover endurance advances through prototype assembly, adding a long-endurance, heavy-payload capability to ZenaTech’s counter-UAS portfolio alongside the Interceptor P-1

ZenaTech, Inc. (Nasdaq:ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech” or the “Company”), a technology solution provider specializing in AI-powered drones, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, provides an update on the ZenaDrone 2000, its heavy-lift autonomous interceptor designed to counter hostile drones and coordinated swarm attacks over land and sea. ZenaDrone is building the first full prototype and part of an integrated defense system, at its facility in Sharjah, UAE, and now expects to begin flight testing in the first quarter of 2027.

Recent build milestones include:

Airframe and folding arm structure completed
Gasoline propulsion system and 36-inch propellers bench-tested
Flight controller and autonomy software in ground testing

Once assembly is complete, the first flight test phase will validate takeoff, hover and landing at full and partial payload, endurance toward the 4+ hour hover rating, the 360-degree detection system, and autonomous navigation. Later phases are expected to add autonomous threat pursuit, multi-target engagement, swarm coordination with the Interceptor P-1, and maritime launch and recovery from ZenaDrone’s IQ Glider marine launch and refueling station.

The ZenaDrone 2000 is designed to fill a gap between small, single-use interceptors and costly missile-based air defense. Its long endurance capability allows it to stay airborne over a base, port, vessel or border crossing for hours, while its 40 kg payload supports heavier sensors and counter-drone effectors. Paired with the low-cost Interceptor P-1, which recently began its own flight testing, it is designed to give defense customers a layered system: the ZenaDrone 2000 watches and coordinates, and P-1 interceptors engage.

“The ZenaDrone 2000 is the largest and most capable aircraft we have built, and we are taking the time to get the prototype right before it flies,” said Shaun Passley, Ph.D., CEO of ZenaTech. “Militaries, navies and border agencies need counter-drone systems that can stay on station for hours and respond to many threats at once, at a cost they can field at scale. With the Interceptor P-1 already inflight testing and the ZenaDrone 2000 moving through its build, we are assembling a complete, affordable counter-UAS layer for the U.S., our allies and partners in the Middle East for a counter-UAS market that industry analysts indicate could exceed USD $20 billion by 2030.”

Recent conflicts across the Middle East and beyond have exposed a glaring imbalance in modern air defense economics. Gulf nations and their allies have been forced to deploy interceptor missiles costing hundreds of thousands — or even millions — of dollars to destroy drones from hostile nations that could be valued at $20,000. This unsustainable cost asymmetry is being exploited by adversaries who can field swarms of low-cost, slow-moving aerial threats faster than conventional defense systems can economically respond. The global defense community has recognized that the most practical, scalable, and affordable answer to the drone threat is not another expensive missile — it is a better, smarter, faster drone.

ZenaTech expects to announce further updates on the ZenaDrone 2000 as milestones are achieved and as the prototype build is complete.

About ZenaTech

ZenaTech, Inc. (Nasdaq:ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries including land surveys and inspections, driving drone-based scalable and recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for agriculture and logistics, as well as ISR, cargo, and counter-UAS applications for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives.

About ZenaDrone

ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, and the IQ Aqua for underwater applications. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.

Contacts for more information:

Company, Investors, and Media: Linda Montgomery ZenaTech 312-241-1415 [email protected]

Investors: Michael Mason CORE IR [email protected]

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated; ZenaTech’s ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and its needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks and uncertainties disclosed under the heading “Risk Factors” in the Company’s Form F-1, Form 20-F and other filings filed with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at www.sec.gov. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

Featured Image @ ZenaTech, Inc.

Contacts

Company, Investors, and Media
Linda Montgomery
ZenaTech
[email protected]
Investors
Michael Mason
CORE IR
[email protected]

Indulgence Spending Is Still Growing, and These 4 Companies Are Building on It (TRWD, RICK, BUD, MO)

financewire — Tue, 06 Oct 2026 12:00:16 +0000

Naples, United States, October 6th, 2026, NewsDirect

Spending on nights out and other forms of consumer indulgence has continued to hold up even as households keep a closer eye on their budgets. Sales at U.S. restaurants and bars were up 5.8% year over year in August 2026, according to the Census Bureau, while a Capgemini survey of 12,000 consumers found that seven in ten people turn to small indulgences to cope with financial pressure. From nightlife and hospitality to beer and nicotine, these are habits a lot of people keep even when they cut back elsewhere.

Adult nightlife is a particularly fragmented part of that economy, with a large number of independently operated venues and a range of businesses supporting them. That structure creates opportunities for companies that acquire and operate venues and for businesses that provide the technology, payments, marketing, and other services those venues rely on.

Tradewinds Universal (OTCID: TRWD) is a holding company that acquires and scales adult hospitality businesses and related technologies, and it’s pursuing both sides of that opportunity. The company is working toward a network of more than 100 venues through acquisitions, licensing, payment systems, and management services. Its strategy is now expanding beyond owned businesses, with licensing agreements designed to bring TRWD‘s technology and services to additional nightlife operators.

TRWD recently announced that it has signed its first U.S. licensing agreement, bringing its revenue-producing relationships into the domestic adult nightlife and hospitality market. The U.S. licensee has relationships with a range of nightlife operators, including those associated with Peppermint Hippo, Las Toxícas, and other brands, which gives TRWD a network of potential participating businesses for its technology and services. Revenue under the agreement is projected to begin during the fourth quarter of 2026.

The U.S. deal follows TRWD‘s first licensing agreement, which covers the Latin American nightlife market. Under that agreement, the licensee paid a $50,000 non-refundable upfront deposit, and TRWD also receives a negotiated share of revenue from participating partners.

“This is what execution looks like,” said Andrew Read, CEO of TRWD. “In a matter of weeks, we have gone from introducing this strategy to signing agreements covering Latin America and now the United States. More importantly, we are entering the revenue stage.”

The licensing model lets operators bring TRWD‘s technology and services into their venues without selling them. The platform is designed to participate in recurring economics around nightlife operations, including communications technology, marketing, customer retention, lead management, payment-related services, ATM services, and management.

“The U.S. agreement is particularly exciting because the licensee already has relationships across an established network of operators,” Read said. “That gives us the opportunity to introduce TRWD technology and services across additional businesses and participate in a broader range of revenue opportunities.”

To put the opportunity in context, TRWD pointed to publicly reported industry data. RCI Hospitality Holdings (Nasdaq: RICK) reported about $242.5 million in fiscal 2025 nightclub revenue across 59 locations, or roughly $4.1 million per location, and estimates that about 2,000 adult nightclubs across North America generate more than $5 billion in annual revenue. Based on those benchmarks, TRWD said a network of 100 participating venues could represent roughly $250 million to more than $400 million in underlying annual venue revenue. The company noted that it would take part in selected portions of those economics through ownership, licensing, and services, and that the revenue it actually recognizes will depend on contract terms, participating businesses, services deployed, and other factors.

Licensing is built to work alongside acquisitions, and the 100-plus venue target stays the same. “Our goal of more than 100 venues has not changed,” Read said. “What has changed is the number of paths available to reach it. We can acquire businesses, build licensing relationships, and generate revenue across both at the same time.”

TRWD has also filed to change its SIC code to 6719, the code for offices of holding companies, and its longer-term objective is an uplisting to a senior U.S. exchange such as Nasdaq. “We believe we’re building a clear path toward seven-figure and ultimately eight-figure annual revenues,” Read said. “We laid out the strategy. Now we are executing it.”

RCI Hospitality Holdings (Nasdaq: RICK) runs adult nightclubs and Bombshells, a chain of restaurants and sports bars. During its fiscal third quarter, the company operated 56 nightclub locations and 12 Bombshells.

Bombshells has become a growing part of the business. RCI recently reported that Bombshell sales rose 25.9% to $10.8 million in the quarter, with same-store sales up 4.7%. New locations in Denver, Lubbock, and Rowlett contributed $2.5 million in sales. Interim President and CEO Travis Reese pointed to Bombshells’ performance as the main driver of the quarter’s growth and said a strong sports lineup helped offset some softness earlier in the period tied to geopolitical uncertainty.

On the nightclub side, RCI has been reformatting older venues, and four of those reformatted clubs brought in $4.0 million during the quarter. Total nightclub sales came in at $62.5 million, up 1.0% from a year earlier. Altogether, club and sports bar sales reached $73.3 million, a 4.0% increase, while combined same-store sales were close to flat at down 0.2%.

RCI also declared its 42nd consecutive quarterly cash dividend at $0.08 per share. With Bombshells expanding and more reformatted clubs back in operation, the company is heading into its next quarter with a broader mix of venues than it had a year ago.

Anheuser-Busch InBev (NYSE: BUD) is the world’s largest brewer, with brands including Budweiser, Corona, Stella Artois, and Michelob Ultra sold in markets around the world.

Some of the company’s fastest growth is coming from outside traditional beer. In its second quarter results, AB InBev reported that revenue from no-alcohol beer rose 27%, and its Beyond Beer category grew 44%. Its BEES Marketplace, a digital platform for retailers, grew gross merchandise value 50% to $1.2 billion.

The core beer business held up as well. Revenue reached $16.66 billion with organic growth of 5.6%, and revenue per hectoliter rose 4.2% as customers traded up to premium brands. Outside their home markets, Corona revenue grew 17%, Stella Artois grew 19%, and Michelob Ultra grew 21%. Beer volumes rose 1.1%, with record second quarter volumes in Mexico, Colombia, and Ecuador.

Normalized EBITDA grew 5.8% to $5.94 billion with a 35.6% margin, and underlying EPS rose 23.4% to $1.21. CEO Michel Doukeris credited investment in the company’s megabrands, innovation, and more choices across more occasions for strengthening its brands with consumers. AB InBev gained or held market share in 70% of its markets during the quarter.

Altria Group (NYSE: MO) owns Philip Morris USA, the maker of Marlboro, along with Helix, the company behind on! nicotine pouches.

Helix has become a big focus for Altria as nicotine pouches take up more of the market, making up 59.9% of the U.S. oral tobacco category in the second quarter, up 8.1 points from a year earlier. The company recently reported that on! PLUS is now in 120,000 stores nationwide, with more line extensions planned and new flavors set to launch in the fourth quarter. In cigarettes, Philip Morris USA is working both ends of the market, with Marlboro Cowboy Cut drawing strong interest from premium smokers, and the discount brand Basic is gaining traction.

For the second quarter, Altria reported net revenues of $6.1 billion, about flat with the prior year, and adjusted diluted EPS of $1.48, up 2.8%. The first half adjusted diluted EPS rose 4.9% to $2.80. CEO Sal Mancuso said the company’s first-half performance gave it the confidence to narrow its full-year 2026 guidance to a range of $5.61 to $5.72 per share, which would be 3.5% to 5.5% growth over 2025.

Altria returned nearly $3.9 billion to shareholders through dividends and buybacks in the first half, including 5.3 million shares repurchased at an average price of $62.78. With more pouches on shelves and new flavors in the pipeline, Altria continues to build out its smoke-free lineup.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Tradewinds Universal to assist in the production and distribution of content related to TRWD. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

About RazorPitch

RazorPitch is an investor relations and investor marketing firm specializing in Non-Traditional Investor Relations for public companies. RazorPitch complements traditional IR with digital-first investor visibility, retail investor engagement, and ongoing investor communications.

razorpitch.com

Contact

Editor
Mark McKelvie
RazorPitch
[email protected]
585-301-7700

G6 Hospitality and FBI Partner to Combat Human Trafficking

newsdirect — Mon, 05 Oct 2026 16:00:15 +0000

Dallas, Texas, October 5th, 2026, NewsDirect

G6 Hospitality, parent company of the Motel 6 and Studio 6 brands, has announced a nationwide partnership with the Federal Bureau of Investigation (FBI) to strengthen efforts to combat human trafficking across its hotel network. The partnership will focus on technology-driven prevention, intelligence sharing, employee and franchisee training, and closer collaboration with law enforcement agencies.

As an initial step, G6 Hospitality and the FBI have identified a select group of properties in Texas where enhanced attention and intervention are required. The organizations are working closely to facilitate timely information sharing, strengthen awareness and training, and support appropriate investigative efforts at these properties. Insights and learnings from the initial phase will help inform the expansion of the partnership across G6’s nationwide network.

A key pillar of the partnership is the continued enhancement of Protect24.ai, an advanced security intelligence platform to proactively monitor escort advertising on online platforms and respond to potential safety and security risks. Following feedback from the FBI, G6 Hospitality is working closely with the platform team to introduce an age-range filter. This will help teams to more efficiently identify and assess potential risk indicators tied to online activity.

G6 Hospitality and the FBI are also developing a nationwide Human Trafficking Conferences. The conference will bring together law enforcement representatives and G6 Hospitality franchisees to strengthen relationships, share emerging investigative trends and best practices, and enhance proactive prevention efforts across the G6 Hospitality portfolio.

Ankit Tandon, Vice Chairman, G6 Hospitality said, “Safety is strongest when industry and law enforcement work together with a shared understanding of the risks and a commitment to act on information. We value the FBI’s guidance and are committed to turning these insights into concrete actions that help make our hotels safer and less vulnerable to human trafficking.”

The initiative is designed to create a stronger connection between hotel operators and law enforcement agencies, helping franchisees understand emerging trafficking patterns while giving law enforcement greater insight into the hotel environment and operational realities.

An FBI Spokesperson said, “Human trafficking is a serious crime that requires strong partnerships across communities and industries. The FBI is excited to partner with Motel 6 and Studio 6 to help prevent human trafficking and strengthen awareness through training and education for franchisees and hotel staff.”

Together, G6 Hospitality and FBI aim to translate law enforcement expertise and real-world insights into practical technology solutions. This will enhance intelligence, strengthen prevention capabilities and support safer environments across G6 Hospitality’s properties.

About G6 Hospitality

G6 Hospitality LLC, part of the PRISM portfolio, is the leading economy lodging franchisor, with over 1500 economy lodging locations under the iconic Motel 6 brand and the Studio 6 Extended Stay brand in the United States and Canada. G6 Hospitality is committed to making hospitality accessible to all through responsible business practices and unparalleled opportunities for franchisees to build a legacy through ownership. Both Motel 6 and Studio 6 were recognized in the 2024 Entrepreneur Franchise 500 report, with Motel 6 ranking in the top 50 of all franchises. The Plano, Texas-based company was named a 2024 Leader in Diversity by Dallas Business Journal.

Contact

Anupriya Malik
G6 Hospitality
[email protected]
+91 97911 63065

Redwood AI (CSE: AIRX) (OTCQB: RDWCF) Joins Canadian Research Consortium in Terry Fox-Funded Oncology AI Project

financewire — Mon, 05 Oct 2026 15:41:19 +0000

Austin, Texas, October 5th, 2026, NewsDirect

Disseminated on behalf of Redwood AI Corp.and may include paid advertising.

The company has been named a co-applicant in a competitive Terry Fox Research Institute grant awarded to advance Onco-Innovations’ SynoGraph(TM) oncology platform.
The project will investigate whether causal AI can improve predictions of first-in-human clinical outcomes using preclinical and real-world clinico-genomic data.
Redwood AI will contribute proprietary data integration and physicochemical modelling methods to expand SynoGraph’s predictive capabilities.
The grant supports a project with an estimated budget of $3.5 million and reimburses eligible costs up to 25% of that amount.
Academic partners will provide clinico-genomic and imaging data for research using federated learning, which is intended to support analysis while protecting data privacy.

Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ), developer of an AI-powered platform for real-world applications across multiple critical industries, is joining a Canadian research collaboration backed by the Terry Fox Research Institute, contributing its data integration and chemical modelling expertise to the development of SynoGraph(TM), an artificial intelligence platform being developed by Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) for oncology research.

A September 22 announcement names Onco as lead applicant, with Redwood AI, the Michael Smith Genome Sciences Centre and the Centre de recherche du CHU de Québec-Université Laval as co-applicants. The project, titled “Causal AI to Predict First-in-Human Clinical Outcomes from Preclinical and Real-World Clinico-Genomic Data,” will explore how AI methods can help…

Contact

IBN
www.InvestorBrandNetwork.com
[email protected]